keyword
MENU ▼
Read by QxMD icon Read
search

Clozapine rechallenge

keyword
https://www.readbyqxmd.com/read/28984748/clozapine-induced-agranulocytosis-granulocytopenia-mechanisms-and-monitoring
#1
Michał Wiciński, Mateusz M Węclewicz
PURPOSE OF REVIEW: Clozapine-induced agranulocytosis/granulocytopenia (CIAG) is an uncommon condition, but potentially fatal in consequences. The pathogenesis, despite multiple experiments, is not fully elucidated. The current theory suggests reactive oxygen species - nitrenium ion as the most important factor of CIAG. In this review, mechanism and monitoring of CIAG will be discussed. RECENT FINDINGS: The mechanism of CIAG seems to have an autoimmune background, rather than toxic...
October 4, 2017: Current Opinion in Hematology
https://www.readbyqxmd.com/read/28922288/addition-of-filgrastim-neupogen-for-clozapine-rechallenge-in-the-case-of-parkinson-disease-patient
#2
Joseph Friedman, Edith Yeboah, Matthew Hermenau
No abstract text is available yet for this article.
September 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28817489/the-use-of-granulocyte-colony-stimulating-factor-in-clozapine-rechallenge-a-systematic-review
#3
John Lally, Steffi Malik, Amir Krivoy, Eromona Whiskey, David M Taylor, Fiona P Gaughran, Robert J Flanagan, Aleksandar Mijovic, James H MacCabe
PURPOSE/BACKGROUND: Clozapine is associated with hematological abnormalities, with neutropenia and agranulocytosis of most concern. Granulocyte colony-stimulating factor (G-CSF) has been used to support clozapine rechallenge after neutropenia with the aim of maintaining the neutrophil count. This study aims to explore the practice, use, safety, and efficacy of G-CSF in this context. METHODS/PROCEDURES: We conducted a systematic review to identify all studies investigating or describing G-CSF as a prophylaxis to enable continued clozapine treatment during a rechallenge...
August 16, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28747065/use-of-granulocyte-colony-stimulating-factor-to-prevent-recurrent-clozapine-induced-neutropenia-on-drug-rechallenge-a-systematic-review-of-the-literature-and-clinical-recommendations
#4
Nicholas Myles, Hannah Myles, Scott R Clark, Robert Bird, Dan Siskind
BACKGROUND: Clozapine is the most effective medication for treatment-refractory schizophrenia; however, its use is contraindicated in people who have had previous clozapine-induced neutropenia. Co-prescription of granulocyte-colony stimulating factor may prevent recurrent neutropenia and allow continuation or rechallenge of clozapine. OBJECTIVE AND METHODS: Systematic review of literature reporting the use of granulocyte-colony stimulating factor to allow rechallenge or continuation of clozapine in people with previous episodes of clozapine-induced neutropenia...
October 2017: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/28481767/development-of-atrial-flutter-after-initiation-of-clozapine-and-successful-rechallenge-without-recurrence
#5
Matt Perdue, Tim Botello
No abstract text is available yet for this article.
August 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27703781/inflammatory-response-to-clozapine-in-the-absence-of-myocarditis-case-report
#6
Patrick Davey, Siobhan Gee, Sukhi S Shergill
SUMMARY: A case is presented of a 25-year-old man with treatment-resistant paranoid schizophrenia whose only previous trial of clozapine had been stopped following a suspected clozapine-induced myocarditis. Due to the failure of his psychosis to respond to a number of antipsychotic treatments and augmentation strategies, clozapine was restarted on admission. His rechallenge was marked by intermittent pyrexia, tachycardia and elevated C-reactive protein (CRP), but eosinophilia was absent...
May 2016: BJPsych Open
https://www.readbyqxmd.com/read/27440213/rapid-rechallenge-with-clozapine-following-pronounced-myocarditis-in-a-treatment-resistant-schizophrenia-patient
#7
Pichai Ittasakul, Anthony Archer, Jennifer Kezman, Wanlop Atsariyasing, Morris B Goldman
Clozapine is an atypical antipsychotic which is often effective in patients who fail to respond to other antipsychotics, but its use carries substantial risk. Myocarditis is one of the life-threatening adverse effects, which occurs in about 1% of exposed patients. Rechallenge with clozapine is controversial, particularly shortly after the occurrence of the myocarditis, and when there is clear and convincing evidence of cardiac damage. Aggressive use of clozapine, however, may be critical for the recovery of patients early in the course of their illness...
2016: Clinical Schizophrenia & related Psychoses
https://www.readbyqxmd.com/read/27324147/successful-rechallenge-with-clozapine-after-treatment-associated-eosinophilia
#8
Peter A McArdle, Dan J Siskind, Uday Kolur, Stephen Parker, Nicole Korman, Subramanian Purushothaman
OBJECTIVE: Eosinophilia has been associated with the use of clozapine. Where clozapine associated eosinophilia develops, and is associated with organ specific damage, clozapine is usually ceased. In cases of treatment associated eosinophilia without evidence of organ specific damage, clozapine would also typically be withdrawn. There are small numbers of reports in the literature describing patients who have had a successful rechallenge of clozapine having previously stopped treatment due to eosinophilia without associated organ specific inflammation...
August 2016: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/27232877/clozapine-rechallenge-after-neutropenia-or-leucopenia
#9
Cintia R Prokopez, Arnaldo R Armesto, María F Gil Aguer, María V Balda, Rosa M Papale, Inés M Bignone, Federico M Daray
To rechallenge with clozapine for a patient who previously has experienced neutropenia or leucopenia or during clozapine treatment is a difficult clinical decision. Herein, we analyzed the results of such a rechallenge in 19 patients. We analyzed all the reports, from the database of the pharmacovigilance department of the Argentine National Administration of Drugs, Foods, and Medical Devices, of patients who were rechallenged with clozapine after a leucopenia or a neutropenia. Nineteen cases of rechallenge after leucopenia or neutropenia were reported between 1996 and 2014...
August 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27109327/-clozapine-rechallenge-after-neutropenia-in-resistant-schizophrenia-a-review
#10
REVIEW
L Simon, F Cazard
INTRODUCTION: Clozapine is an atypical antipsychotic known for its efficacy in refractory schizophrenia. One of the adverse effects is neutropenia. This dysplasia is a rare but major side effect which leads to a discontinuation and constitutes further contraindication. Thereafter, therapeutic options decrease dramatically. Mechanisms involved are not well known at this time and can be combined. A toxic hypothesis may be more likely than an immune-allergic one. METHODS: We have reviewed publications on Medline describing procedures that allowed clozapine rechallenge after blood dyscrasia in refractory schizophrenia...
August 2016: L'Encéphale
https://www.readbyqxmd.com/read/26913176/continuing-clozapine-treatment-with-lithium-in-schizophrenic-patients-with-neutropenia-or-leukopenia-brief-review-of-literature-with-case-reports
#11
REVIEW
Memduha Aydin, Bilge Cetin Ilhan, Saliha Calisir, Seda Yildirim, Ibrahim Eren
OBJECTIVE: Clozapine is a second-generation antipsychotic used for treatment-resistant schizophrenia. Despite its effectiveness, clozapine is largely underused due to serious side effects such as leukopenia or neutropenia. We aimed to review whether to continue, discontinue or rechallenge clozapine treatment after such haematological side effects. METHODS: We reviewed and summarized the literature on the use of clozapine, how to deal with its side effects, and suitable options in case of any haematological problems...
February 2016: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/26876947/pharmacogenomic-study-of-clozapine-induced-agranulocytosis-granulocytopenia-in-a-japanese-population
#12
Takeo Saito, Masashi Ikeda, Taisei Mushiroda, Takeshi Ozeki, Kenji Kondo, Ayu Shimasaki, Kohei Kawase, Shuji Hashimoto, Hidenaga Yamamori, Yuka Yasuda, Michiko Fujimoto, Kazutaka Ohi, Masatoshi Takeda, Yoichiro Kamatani, Shusuke Numata, Tetsuro Ohmori, Shu-Ichi Ueno, Manabu Makinodan, Yosuke Nishihata, Masaharu Kubota, Takemi Kimura, Nobuhisa Kanahara, Naoki Hashimoto, Kiyoshi Fujita, Kiyotaka Nemoto, Taku Fukao, Taro Suwa, Tetsuro Noda, Yuji Yada, Manabu Takaki, Naoya Kida, Taku Otsuru, Masaru Murakami, Atsushi Takahashi, Michiaki Kubo, Ryota Hashimoto, Nakao Iwata
BACKGROUND: Clozapine-induced agranulocytosis (CIA)/clozapine-induced granulocytopenia (CIG) (CIAG) is a life-threatening event for schizophrenic subjects treated with clozapine. METHODS: To examine the genetic factor for CIAG, a genome-wide pharmacogenomic analysis was conducted using 50 subjects with CIAG and 2905 control subjects. RESULTS: We identified a significant association in the human leukocyte antigen (HLA) region (rs1800625, p = 3...
October 15, 2016: Biological Psychiatry
https://www.readbyqxmd.com/read/26646037/optimizing-outcomes-in-clozapine-rechallenge-following-neutropenia-a-cohort-analysis
#13
Nicholas Meyer, Siobhan Gee, Eromona Whiskey, David Taylor, Aleksandar Mijovic, Fiona Gaughran, Sukhi Shergill, James H MacCabe
OBJECTIVE: Certain patients with treatment-refractory schizophrenia may be rechallenged with clozapine following previous neutropenia. Evidence guiding patient selection and the effectiveness of lithium and granulocyte-colony stimulating factor (G-CSF) in rechallenge is limited, and factors associated with successful outcomes are unclear. METHOD: Outcomes were studied in patients rechallenged with clozapine at a tertiary referral center between January 2007 and December 2013, following 1 or more previous trials terminated due to neutropenia, defined as an absolute neutrophil count (ANC) < 1...
November 2015: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/26613551/antipsychotic-reexposure-and-recurrent-pneumonia-in-schizophrenia-a-nested-case-control-study
#14
Galen Chin-Lun Hung, Hsing-Cheng Liu, Shu-Yu Yang, Chun-Hung Pan, Ya-Tang Liao, Chiao-Chicy Chen, Chian-Jue Kuo
OBJECTIVE: Few studies have used systematic datasets to assess the safety of antipsychotic rechallenge after an adverse event. This nested case-control study estimated the risk for recurrent pneumonia after reexposure to antipsychotic treatment. METHOD: In a nationwide schizophrenia (ICD-9-CM code 295) cohort (derived from the National Health Insurance Research Database in Taiwan) who were hospitalized for pneumonia (ICD-9-CM codes 480-486, 507) between 2000 and 2008 (N = 2,201), we identified 494 subjects that developed recurrent pneumonia after a baseline pneumonia episode...
January 2016: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/26602627/clozapine-induced-myocarditis-prevention-and-considerations-in-rechallenge
#15
Sarah C Cook, Britnay A Ferguson, Robert O Cotes, Thomas W Heinrich, Ann C Schwartz
No abstract text is available yet for this article.
November 2015: Psychosomatics
https://www.readbyqxmd.com/read/26565383/maximizing-clozapine-utilization-while-minimizing-blood-dyscrasias-evaluation-of-patient-demographics-and-severity-of-events
#16
COMPARATIVE STUDY
Tammie Lee Demler, Nicole E Morabito, Charlene E Meyer, Lewis Opler
The aim of this study was to determine whether patient characteristics such as age, sex, race/ethnicity, and frequency of monitoring play a role in clozapine-related blood dyscrasias. This study examined all neutropenic events to identify any potential demographic qualities that may pose increased risk to individuals receiving clozapine treatment in accordance with the FDA guidelines released in 2005. These guidelines required the addition of absolute neutrophil count (ANC) tests in addition to white blood cell (WBC) counts to regular monitoring and a reduction in the frequency of testing to once monthly after 1 year of satisfactory WBC counts and ANCs...
March 2016: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/26373547/eosinophilia-and-parotitis-occurring-early-in-clozapine-treatment
#17
Bochra Nourhène Saguem, Saoussen Bouhlel, Chaker Ben Salem, Bechir Ben Hadj Ali
CASE PRESENTATION: Mr. S is a 32-year-old male with schizophrenia. Due to poor responses to various antipsychotic medications, he was started on clozapine with the dose titrated to 300 mg/day during a 4-week period. The weekly checks of the complete blood cell count showed gradual increases in the eosinophil count from normal values to 4320 per mm(3). Mr. S did not have any symptoms except some increased salivation. Clozapine was suspended, and eosinophils gradually began to decline to the normal range...
December 2015: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/25339121/burning-pain-secondary-to-clozapine-use-a-case-report
#18
Bradley Linton, Rachel Fu, Penny A MacDonald, Hooman Ganjavi
BACKGROUND: The first of the atypical antipsychotics introduced in the 1970s, clozapine remains the most efficacious neuroleptic to this day. However, serious and potentially fatal side effects have necessitated careful regular monitoring among prescribing clinicians. Some adverse effects (e.g. ischaemic bowel) remain under recognized, while newly identified adverse effects continue to be described in the literature. CASE PRESENTATION: In this report, we describe a healthy 43-year old Caucasian male who experienced onset of a full body deep burning pain several months after the onset of treatment with clozapine...
2014: BMC Psychiatry
https://www.readbyqxmd.com/read/24633526/rechallenging-clozapine-after-neuroleptic-malignant-syndrome
#19
Emaya Anbalagan, Muaid Ithman, John Lauriello
Neuroleptic malignant syndrome (NMS) is a potentially fatal manifestation of antipsychotic use associated with symptoms that include mental status changes, muscle rigidity, fever and autonomic dysfunction. An occurrence of NMS with clozapine has been reported in the past but there are very few reports of successfully rechallenging the drug in individuals who have developed the syndrome. This case report discusses one of the few instances in literature where clozapine has been re-administered successfully to a patient without a reoccurrence of NMS...
September 2014: Psychiatric Quarterly
https://www.readbyqxmd.com/read/24299466/discontinuation-of-clozapine-a-15-year-naturalistic-retrospective-study-of-320-patients
#20
M C Davis, M A Fuller, M E Strauss, P E Konicki, G E Jaskiw
OBJECTIVE: Clozapine is underutilized in the management of treatment-resistant schizophrenia. To understand contributing factors, we analyzed the frequency and causes of clozapine discontinuations that occurred over a 15-year period in a clinical setting. METHOD: Data were extracted from computerized records and from mandatory termination reports for discontinuation events 1993-2007. The reasons for termination were analyzed. RESULTS: Over half of the patients (n = 183/320; 57%) had at least one discontinuation (median time 609 days)...
July 2014: Acta Psychiatrica Scandinavica
keyword
keyword
103139
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"